Extract
Cardiovascular and respiratory diseases are major contributors to global deaths [1]. Although low lung function is a risk factor for early death, like hypertension and hypercholesterolaemia [2], evaluation of lung function in primary care is not prioritised as highly as blood pressure or cholesterol measurements [3]. Also, public health authorities have remained silent on major health challenges other than smoking relevant for development and preservation of normal lung function from birth to old age. It is now increasingly evident that low lung function in childhood may affect general health throughout life [4–8]. It therefore seems likely that improvement of lung function on a population-scale may be associated with lower morbidity and mortality. We therefore tested the hypothesis that supernormal lung function is associated with lower morbidity and mortality.
Abstract
Supernormal lung function is associated with fewer cardiovascular and respiratory events and a survival benefit independent from major risk factors https://bit.ly/371l3ut
Footnotes
Author contributions: Y. Çolak and S. Afzal had full access to all the data in the study and had final responsibility for the decision to submit for publication. Y. Çolak, B.G. Nordestgaard, J. Vestbo, P. Lange and S. Afzal contributed to the study concept and design. Y. Çolak, B.G. Nordestgaard, J. Vestbo, P. Lange and S. Afzal collected, analysed, or interpreted the data. Y. Çolak wrote the draft manuscript and performed the statistical analyses. Y. Çolak, B.G. Nordestgaard, J. Vestbo, P. Lange and S. Afzal revised the manuscript for important intellectual content. B.G. Nordestgaard obtained funding. B.G. Nordestgaard provided administrative, technical, or material support. S. Afzal supervised the study.
Conflict of interest: B.G. Nordestgaard has nothing to disclose.
Conflict of interest: J. Vestbo reports personal fees for consultancy from GlaxoSmithKline, Chiesi Pharmaceuticals, Boehringer Ingelheim, Novartis, Almirall, AstraZeneca and Bioxydyn, personal fees for lectures from GlaxoSmithKline, Chiesi Pharmaceuticals, Novartis, AstraZeneca and Boehringer Ingelheim, outside the submitted work; and the author's spouse is a former employee of GlaxoSmithKline, AstraZeneca and Ferring.
Conflict of interest: P. Lange reports grants and personal fees from Almirall, Boehringer Ingelheim and GSK, personal fees from AstraZeneca, Novartis, Nycomed, Pfizer and Mundipharma, outside the submitted work.
Conflict of interest: S. Afzal has nothing to disclose.
Conflict of interest: Y. Çolak reports personal fees from Boehringer Ingelheim, AstraZeneca and Sanofi Genzyme outside the submitted work.
Support statement: This study was funded by the Lundbeck Foundation. The funder had no role in the design and conduct of the study; collection, management, analysis, or interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication. Y. Çolak and S. Afzal had full access to all data in the study and had final responsibility for the decision to submit for publication. Funding information for this article has been deposited with the Crossref Funder Registry.
- Received September 3, 2020.
- Accepted November 13, 2020.
- Copyright ©ERS 2021